Myles HelfandExecutive Editor
Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.
Latest by Myles Helfand
Nov. 14, 2019: Psychiatric disorders, adherence, and viral suppression; depression and adherence among women with HIV; using hair to link food insecurity and HIV viremia; a point-of-care test for tenofovir adherence.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
Oct. 24, 2019: A computerized antiretroviral recommendation tool; higher Fiebig stage equals more frequent viral load blips; low prescription refill rates among Americans starting treatment; internalized stigma and HIV outcomes.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
Oct. 3, 2019: The sexual divide in HIV-related heart disease; weight gain among women on integrase inhibitors; HIV's association with non-specific health conditions; hopeful trends in self-reported neurocognitive impairment.
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.